333 related articles for article (PubMed ID: 22895527)
1. Evaluation of the interactions of HIV-1 integrase with small ubiquitin-like modifiers and their conjugation enzyme Ubc9.
Li Z; Wu S; Wang J; Li W; Lin Y; Ji C; Xue J; Chen J
Int J Mol Med; 2012 Nov; 30(5):1053-60. PubMed ID: 22895527
[TBL] [Abstract][Full Text] [Related]
2. Effect of endosulfan and bisphenol A on the expression of SUMO and UBC9.
Yarahalli Jayaram V; Baggavalli S; Reddy D; Sistla S; Malempati R
Drug Chem Toxicol; 2020 Nov; 43(6):637-644. PubMed ID: 30426790
[TBL] [Abstract][Full Text] [Related]
3. Identification of a non-covalent ternary complex formed by PIAS1, SUMO1, and UBC9 proteins involved in transcriptional regulation.
Mascle XH; Lussier-Price M; Cappadocia L; Estephan P; Raiola L; Omichinski JG; Aubry M
J Biol Chem; 2013 Dec; 288(51):36312-27. PubMed ID: 24174529
[TBL] [Abstract][Full Text] [Related]
4. Noncovalent SUMO-interaction motifs in HIV integrase play important roles in SUMOylation, cofactor binding, and virus replication.
Zheng Y; Jayappa KD; Ao Z; Qiu X; Su RC; Yao X
Virol J; 2019 Apr; 16(1):42. PubMed ID: 30940169
[TBL] [Abstract][Full Text] [Related]
5. Site-specific inhibition of the small ubiquitin-like modifier (SUMO)-conjugating enzyme Ubc9 selectively impairs SUMO chain formation.
Wiechmann S; Gärtner A; Kniss A; Stengl A; Behrends C; Rogov VV; Rodriguez MS; Dötsch V; Müller S; Ernst A
J Biol Chem; 2017 Sep; 292(37):15340-15351. PubMed ID: 28784659
[TBL] [Abstract][Full Text] [Related]
6. Spatiotemporal distribution of SUMOylation components during mouse brain development.
Hasegawa Y; Yoshida D; Nakamura Y; Sakakibara S
J Comp Neurol; 2014 Sep; 522(13):3020-36. PubMed ID: 24639124
[TBL] [Abstract][Full Text] [Related]
7. Small ubiquitin-like modifier 1-3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival.
Yang W; Wang L; Roehn G; Pearlstein RD; Ali-Osman F; Pan H; Goldbrunner R; Krantz M; Harms C; Paschen W
Cancer Sci; 2013 Jan; 104(1):70-7. PubMed ID: 23078246
[TBL] [Abstract][Full Text] [Related]
8. Enhanced detection of in vivo SUMO conjugation by Ubc9 fusion-dependent sumoylation (UFDS).
Niedenthal R
Methods Mol Biol; 2009; 497():63-79. PubMed ID: 19107411
[TBL] [Abstract][Full Text] [Related]
9. SUMO modification of Akt regulates global SUMOylation and substrate SUMOylation specificity through Akt phosphorylation of Ubc9 and SUMO1.
Lin CH; Liu SY; Lee EH
Oncogene; 2016 Feb; 35(5):595-607. PubMed ID: 25867063
[TBL] [Abstract][Full Text] [Related]
10. Dynamin interacts with members of the sumoylation machinery.
Mishra RK; Jatiani SS; Kumar A; Simhadri VR; Hosur RV; Mittal R
J Biol Chem; 2004 Jul; 279(30):31445-54. PubMed ID: 15123615
[TBL] [Abstract][Full Text] [Related]
11. Sumoylation of human argonaute 2 at lysine-402 regulates its stability.
Sahin U; Lapaquette P; Andrieux A; Faure G; Dejean A
PLoS One; 2014; 9(7):e102957. PubMed ID: 25036361
[TBL] [Abstract][Full Text] [Related]
12. Assessing the Role of Paralog-Specific Sumoylation of HDAC1.
Citro S; Chiocca S
Methods Mol Biol; 2017; 1510():329-337. PubMed ID: 27761832
[TBL] [Abstract][Full Text] [Related]
13. Interaction between
Yi J; Wang Y; Li Q; Zhang H; Shao Z; Deng X; He J; Xiao C; Wang Z; Wang Y; Chen C
J Vet Sci; 2019 Sep; 20(5):e54. PubMed ID: 31565897
[No Abstract] [Full Text] [Related]
14. Modification of papillomavirus E2 proteins by the small ubiquitin-like modifier family members (SUMOs).
Wu YC; Roark AA; Bian XL; Wilson VG
Virology; 2008 Sep; 378(2):329-38. PubMed ID: 18619639
[TBL] [Abstract][Full Text] [Related]
15. Interaction of moloney murine leukemia virus capsid with Ubc9 and PIASy mediates SUMO-1 addition required early in infection.
Yueh A; Leung J; Bhattacharyya S; Perrone LA; de los Santos K; Pu SY; Goff SP
J Virol; 2006 Jan; 80(1):342-52. PubMed ID: 16352559
[TBL] [Abstract][Full Text] [Related]
16. A stable chemical SUMO1-Ubc9 conjugate specifically binds as a thioester mimic to the RanBP2-E3 ligase complex.
Sommer S; Ritterhoff T; Melchior F; Mootz HD
Chembiochem; 2015 May; 16(8):1183-9. PubMed ID: 25917782
[TBL] [Abstract][Full Text] [Related]
17. NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation.
Licciardello MP; Müllner MK; Dürnberger G; Kerzendorfer C; Boidol B; Trefzer C; Sdelci S; Berg T; Penz T; Schuster M; Bock C; Kralovics R; Superti-Furga G; Colinge J; Nijman SM; Kubicek S
Oncogene; 2015 Jul; 34(29):3780-90. PubMed ID: 25263445
[TBL] [Abstract][Full Text] [Related]
18. MEL-18 interacts with HSF2 and the SUMO E2 UBC9 to inhibit HSF2 sumoylation.
Zhang J; Goodson ML; Hong Y; Sarge KD
J Biol Chem; 2008 Mar; 283(12):7464-9. PubMed ID: 18211895
[TBL] [Abstract][Full Text] [Related]
19. SUMO Ubc9 enzyme as a viral target.
Varadaraj A; Mattoscio D; Chiocca S
IUBMB Life; 2014 Jan; 66(1):27-33. PubMed ID: 24395713
[TBL] [Abstract][Full Text] [Related]
20. Enhanced SUMOylation of proteins containing a SUMO-interacting motif by SUMO-Ubc9 fusion.
Kim ET; Kim KK; Matunis MJ; Ahn JH
Biochem Biophys Res Commun; 2009 Oct; 388(1):41-5. PubMed ID: 19635459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
